Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Provence Technologies Increases its Capital to EUR One Million

Published: Thursday, September 06, 2012
Last Updated: Thursday, September 06, 2012
Bookmark and Share
Underpinned by a stronger financial structure, the company will develop new projects for rehabilitating compounds of proven therapeutic potential.

Provence Technologies announces today that it has increased its capital by EUR 800,000 to EUR one million through a transfer from reserves. The company has greatly strengthened its financial structure since it was founded in 1998 and has succeeded in creating a solid shareholder base.
 
“We are particularly happy about this capital increase, which confirms our shareholders’ confidence in the future of Provence Technologies,” said Christophe Baralotto, the company’s CFO. “For all our partners, suppliers and clients, the increase is a guarantee of sustainability.”
 
Provence Technologies combines a traditional CRO (contract research organization) business for clients in the pharmaceutical, agrochemical and cosmetics industries with a high-value-added research activity based on its innovative technologies. Thanks to this balanced business model, the company has funded its research programs through its fee-for-service activities and has thus created a virtuous circle, with revenues derived from its own products. Provence Technologies is thus pushing ahead with research and development programs focused on compounds which are known for their high therapeutic potential but which have been neglected or abandoned up to now because of poor quality.
 
“The increased capital will enable Provence Technologies to support its growth strategy and fully develop its R&D programs,” said the company’s chairman, Michel Feraud. “Since it was founded, our company has sought, among other projects, to uncover the therapeutic potential of abandoned compounds, as it did with methylene blue. We want to continue down this path, which not only creates value for the company but also gives patients the benefit of these drugs.”
 
To carry this R&D strategy forward, two new researchers will join Provence Technologies at the end of 2012. The company is also planning to move into a new 1,600 square meter building in the Chateau-Gombert technology park in Marseille in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Provence Technologies and NexGenix Announce Successful Lead Compound Development
Both companies have been collaborating on the synthesis optimization and pre industrialization of innovative molecule targeting Hsp90.
Wednesday, July 06, 2011
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!